TH MEDICAL-B

Zhenkang Medical-B opened higher and surged in the morning session, dipping to a low of HK$662.5 before rallying sharply to an intraday high of HK$705, a gain of 5.54%, and closing at the day's peak. The strong early move was fueled by continued enthusiasm over the commercialization of AI-powered surgical robots, following a drop on August 19 that landed it on the top decliners list. Recent coverage (Inside the Silent Rally) highlighted the stock as a niche Hong Kong medtech play attracting capital. Financially, Q4 2025 revenue surged 642.09% YoY to HK$6.675 million, but net loss remained at HK$18.56 million, with a net margin of -278%. The stock trades at HK$705, 20.43% below its 52-week high of HK$886, yet boasts a 76.25% YTD return and sits above its MA20 (HK$701.55) and MA60 (HK$598.68). However, its P/B ratio of 94.75x suggests lingering concerns about profitability.

Zhenkang Medical-B (2697.HK) staged a morning session rally and retreat, hitting an intraday high of HK$693 at 10:24 BJ time before paring gains to close the morning at HK$660, up 3.9% from the previous close of HK$635, yet still 25.5% below the 52-week high of HK$886 and below the 20-day MA (HK$696). Recent news around AI surgical robot commercialization sparked a multi-day rally, with the stock hitting a 52-week high on Aug 18-19, but profit-taking emerged today as the early surge failed to sustain. Financially, Q4 2025 revenue surged 642.09% YoY to HK$6.67 million, but net loss remained at HK$18.56 million with a net margin of -278%, and EPS of -HK$0.5776 narrowed only 10% YoY—no fundamental improvement. The P/B ratio stood at 88.7x, total market cap at ~HK$23.5 billion, with only 156 employees, signaling extreme valuation. However, YTD gain of 65% and price above the 60-day MA (HK$595.671) suggest short-term momentum persists.

Zhenkang Medical-B (2697.HK) closed the morning session up 7.86% at HK$699.500, driven by news of AI-powered surgical robot commercialization. The stock hit a 52-week high of HK$699.500 after opening at HK$650.000, but rebounded from a low of HK$630.000, resulting in an 11.0% intraday range. Q4 2025 revenue surged 642.09% YoY to HK$6.675 million, while net loss narrowed 10.06%, but net profit margin remained deeply negative at -278.04%. The stock is now 11.0% above its 52-week low, though its PE of -249.93 and PB of 94.01 suggest stretched valuation. However, selling expenses and a 12.09% YoY decline in operating profit highlight ongoing commercialization challenges.

Zhenkang Medical-B opened lower in the morning session and extended losses, falling 5.12% to HK$732, with the intraday range widening from HK$783 to HK$732, significantly underperforming the broader market. The stock had recently experienced sharp swings due to AI surgical robot commercialization news, but continued to decline after yesterday's AI healthcare sector correction. Q4 revenue surged 642% YoY to HK$6.67 million, yet net loss stood at HK$18.56 million with a net profit margin of -278%, indicating the company has yet to achieve profitability. The stock is 17.38% below its 52-week high of HK$886, though it remains up 83% YTD and trades below the 20-day moving average of HK$691.6, suggesting near-term technical weakness. Still, revenue growth has exceeded 600% for two consecutive quarters, highlighting accelerating business expansion.

True Health Medical-B opened at HK$780.5 this morning but weakened rapidly, trending down in a single-sided manner to an intraday low of HK$742.5, and was last traded at HK$750.5 as of 10:11 BJ, down about 3.85% from the previous close of HK$780.5. The previous day's rally on AI surgical robot commercialization news quickly gave way to a reassessment of earnings sustainability: Q4 2025 revenue was only HK$6.67M, soaring 642% YoY, yet net loss stood at HK$18.56M with a net margin of -278% and EPS of -HK$0.5776, narrowing just 10% YoY—far from a convincing turnaround, prompting profit-taking. The current price is 15.29% off the 52-week high of HK$886, but still up 87.63% YTD and 10.4% above the MA20 of HK$679.9, with a PB of 100.9x reflecting high growth expectations. While turnover was a mere HK$740K with extremely low volume, suggesting the pullback is primarily short-term profit-taking rather than a structural shift in sentiment.